DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1928)

Bladder Cancer | Landscape & Forecast | Disease Landscape & Forecast

Bladder Cancer | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Market Outlook

Immune checkpoint inhibitors are revolutionizing the treatment algorithm for unresectable locally advanced or metastatic bladder cancer. Following the 2016/7 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients (i.e., second– and later lines)—PD-L1 inhibitor Tecentriq (Roche/Genentech/Chugai) followed by PD-1 inhibitor Opdivo (Bristol-Myers Squibb) and other PD-1/PD-L1 inhibitors—significant sales are forecast for the unresectable locally advanced or metastatic setting. There is now intense Phase II/III pipeline activity, with some drugs in the late-phase pipeline also targeting previously untreated unresectable locally advanced or metastatic bladder cancer (i.e., first-line setting). We anticipate that several new therapies will gain approvals within the forecast period, resulting in increased therapy options.

Questions Answered

  • How large are the clinically and commercially relevant drug-treatable unresectable locally advanced or metastatic bladder cancer populations and how will drug-treatment rates change over time?
  • What is the current state of treatment for unresectable locally advanced or metastatic bladder cancer? What are the (dis)advantages of currently marketed drugs and interviewed experts’ insights on these therapies?
  • What clinical needs remain unfulfilled and what opportunities can developers capitalize on?
  • What pipeline products are most promising, and what sales/uptake could they secure in the unresectable locally advanced or metastatic bladder cancer market? What are the most promising early-phase pipeline products?
  • What are the drivers and constraints in the unresectable bladder cancer market, and how will the market evolve over the ten-year forecast period within the major markets?

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • March 2019
      • December 2018
      • October 2018
      • September 2018
      • August 2018
      • June 2018
      • March 2018
      • November 2017
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Bladder Cancer?
        • What Factors Are Constraining the Market for Bladder Cancer?
      • Segment-Specific Trends
        • Non-Muscle-Invasive Bladder Cancer
        • Localized and Resectable Locally Advanced Muscle-Invasive Bladder Cancer
        • First-Line Unresectable Locally Advanced or Metastatic Bladder Cancer
        • Second- and Third-Line Metastatic Bladder Cancer
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Disease Pathophysiology
      • Staging and Classification
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Bladder Cancer
        • Locally Recurrent Incident Cases of Bladder Cancer
        • Metastatic Recurrent Incident Cases of Bladder Cancer
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Immune Checkpoint Inhibitors
      • Medical Practice
        • Non-Muscle-Invasive Bladder Cancer
        • Localized and Resectable Locally Advanced Muscle-Invasive Bladder Cancer
        • First-Line Unresectable Locally Advanced or Metastatic Bladder Cancer
        • Second- and Third-Line Metastatic Bladder Cancer
        • Treatment Guidelines
        • Drug Selection
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Attainment of Unmet Needs
        • Current and Future Attainment of Unmet Needs in Bladder Cancer
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Angiogenesis Inhibitors
        • Antibody Drug Conjugates
        • FGFR Inhibitors
        • IDO-1 Inhibitors
        • Recombinant Immunotoxins
        • Oncolytic Viral Therapy
        • Cytotoxic Agents
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Bladder Cancer
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Bladder Cancer Bibliography

Already a Client? Log in to access this report.

  • Pub Date: March 2019
  • Author(s): Laura Vinuesa, DVM, MSc; Nishant Kumar, MPH; Grace Mitchell, M.Res
  • Laura Vinuesa, DVM, is a Senior Business Insights Analyst in the Oncology Division at Decision Resources Group, with expertise in thyroid carcinoma and bladder cancer. Previously, Dr. Vinuesa was an EU Market Access Analyst in the Global Market Access Insights Team at Decision Resources Group. She has expertise in market access, pricing and reimbursement, health technology assessment, and health policy. Prior to joining Decision Resources, she worked as Market Access & Institutional Relations Analyst at Pfizer in Spain, providing support for the successful market launch of drugs for different areas: cardiovascular, oncology, mental disorder and rare disease. She is a Doctor of Veterinary Medicine from the Complutense University of Madrid, and holds a in Clinical Research and Pharmaceutical Medicine from EPHOS - School of PharmaStudies. lvinuesa@

  • Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects. His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.

  • is a business insights analyst in the oncology team at Decision Resources Group. Ms. Mitchell previously worked as an analyst at financial PR firm, Tulchan Communications, where she provided news on the pharmaceutical sector from a commercial perspective. Prior to this, Ms. Mitchell was a project assistant within the consulting team at DRG-Abacus where she learnt about HEOR and market access. Ms. Mitchell obtained her Masters in Cancer Sciences from the University of Birmingham. The degree focused on the expression of immune checkpoints in DLBCL. She also holds a in Biomedical Science from the University of Reading.

Purchase Report

Recent reports:
You may also be interested in: